Phio Pharmaceuticals Corp. (PHIO) - 10-K Summary
Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Model: Clinical-stage biopharmaceutical company developing immuno-oncology therapeutics using proprietary INTASYL® self-delivering small interfering RNA (siRNA) technology. The company operates as a single segment with no commercial product revenue to date.
Key Assets: Lead candidate PH-762 (PD-1 silencer) and preclinical candidate PH-894 (BRD4 silencer).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Expenses | $9,220 | $7,387 |
| Net Loss | $(8,698) | $(7,150) |
| Cash and Cash Equivalents (Year-End) | $21,031 | $5,382 |
| Net Cash Used in Operating Activities | $(7,979) | $(7,112) |
| Net Cash Provided by Financing Activities | $23,640 | $3,996 |
| Total Liabilities | $1,340 | $1,015 |
Material Changes vs. Prior Period
- Financing Activity: The company raised approximately $20.6 million in net proceeds during 2025 through three major financing rounds (January, July, and November 2025), compared to $4.0 million in 2024. This significantly improved liquidity, increasing cash balances from $5.4 million to $21.0 million.
- Operating Expenses: Total operating expenses increased by 25% ($1.8 million) to $9.2 million.
- Research & Development (R&D): Increased 27% to $4.6 million, driven primarily by a $740,000 increase in costs for the PH-762 Phase 1b clinical study and higher employee compensation.
- General & Administrative (G&A): Increased 23% to $4.6 million, due to higher outsourced professional accounting ($400k) and legal ($110k) fees, plus increased stock-based compensation.
- Capital Structure: The company completed a 1-for-9 reverse stock split in July 2024. As of December 31, 2025, there were 11.6 million shares of Common Stock outstanding, compared to 1.7 million in 2024 (pre-split adjusted).
Guidance, Outlook, and Risks
- Clinical Progress (PH-762): The Phase 1b trial for PH-762 (intratumoral injection for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma) was fully enrolled in November 2025 with 22 patients. Preliminary data indicates a 65% overall response rate for squamous cell carcinomas, with 9 patients achieving complete response. No dose-limiting toxicities were observed. An FDA submission for guidance on next steps is targeted for Q2 2026.
- Liquidity Outlook: Management believes current cash resources ($21.0 million) are sufficient to meet obligations for at least 12 months from the filing date (March 2026).
- Key Risks:
- Capital Requirements: The company has a history of net losses and expects to continue incurring losses. Substantial additional funding will be required to complete R&D and commercialization.
- Regulatory & Development: Product candidates are in early stages; clinical trials may fail, be delayed, or not lead to regulatory approval.
- Stock Listing: The company must maintain compliance with Nasdaq Capital Market listing requirements, including a minimum bid price of $1.00. Failure to do so could result in delisting.
- Intellectual Property: Reliance on licensed technology (Advirna) and pending patents; potential for infringement claims or patent invalidation.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $21.0 million cash balance against projected burn rates for the PH-762 Phase 2 trial and ongoing operations.
- Dilution Risk: Review the terms of the numerous warrant issuances (Series G through Series A) totaling over 13.5 million warrants outstanding, which represent significant potential dilution.
- Clinical Data Validation: Await the formal analysis of the PH-762 Phase 1b trial data expected in Q2 2026 to confirm the preliminary 65% response rate.
- Nasdaq Compliance: Monitor the stock price to ensure it remains above the $1.00 minimum bid price requirement to avoid delisting proceedings.
- Section 382 Limitations: Assess the impact of ownership changes on the utilization of Net Operating Loss (NOL) carryforwards, which may be limited under IRS Section 382.